

19 June 2019

**Surgical Innovations Group plc  
("Surgical Innovations", or the "Group")**

**Board and management structure changes**

Surgical Innovations (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, provides details of changes to the Board, management structure and responsibilities.

Melanie Ross (CFO) has decided to leave the Group and will do so with effect from 30 June 2019. Melanie led the turnaround of Surgical Innovations in 2014/2015, and has subsequently played a pivotal role in developing the business through her roles as COO and CFO. Following recent organisational changes, Melanie has now expressed her intention to pursue other opportunities.

Melanie will handover her finance responsibilities to Charmaine Day (Company Secretary and Group Financial Controller), who will report directly to David Marsh (CEO). Charmaine is a Fellow of the Chartered Institute of Certified Accountants and joined the Company in 2012 from her previous role as Management Accountant at Ellis Fairbank Plc.

The Group continues to strengthen its operational and compliance team at its Leeds site. As a key part of this process, Steve Seed has accepted a new position as Compliance Director of Surgical Innovations Limited, also reporting to David Marsh, with effect from 2 September 2019. Steve holds an MSc in Medical Technology Regulatory Affairs from Cranfield University and has almost 30 years' experience of responsibility for quality assurance, health and safety and regulatory affairs. Steve joins from Xiros Limited, where he is currently Compliance Director, and previously held the position of Quality Assurance Manager and Head of Regulatory Affairs at Surgical Innovations Group plc between 2006 and 2011.

**Nigel Rogers, Chairman, said:**

*"The Board thanks Melanie for her considerable achievements with the Group during her tenure and wishes her well for the future."*

*"We look forward to Steve joining our team in due course. Steve brings a wealth of knowledge and experience in navigating the increasing challenges presented in the current regulatory environment, and will reinforce our capabilities and streamline processes in this critical area."*

**For further information please contact:**

**Surgical Innovations Group Plc**

Nigel Rogers, Chairman

David Marsh, Chief Executive Officer

[www.sigrouplc.com](http://www.sigrouplc.com)

Tel: 0113 230 7597

**N+1 Singer (Nominated Advisor and Broker)**

Richard Lindley / Rachel Hayes

Tel: 020 7496 3000

**Walbrook PR (Financial PR & Investor Relations)**

Paul McManus / Lianne Cawthorne

Tel: 020 7933 8780 or [si@walbrookpr.com](mailto:si@walbrookpr.com)

Mob: 07980 541 893 / 07584 391 303